<DOC>
	<DOCNO>NCT00651781</DOCNO>
	<brief_summary>The primary aim study : • To analyze efficacy ( order evaluate response ) sequential treatment scheme Bortezomib combination Fludarabine , Cytarabine Idarubicin continue Bortezomib monotherapy patient relapse refractory AML ≥18 year old . The safety aim study : • To evaluate safety tolerance sequential treatment scheme propose Bortezomib combined Fludarabine , Cytarabine Idarubicin monotherapy , measure clinical toxicity laboratory incidence . The biological aim study : • To evaluate Minimal Residual Disease ( MRD ) impact monitor multiparametric flow cytometry carry different moment treatment .</brief_summary>
	<brief_title>Velcaflagida Relapsed Refractary Acute Myeloid Leukemia</brief_title>
	<detailed_description>Initially phase I perform determine appropriate dose Cytarabine use Flag-Ida regimen combination Velcade ; reason , first 9 patient distribute 3 different cohort 3 patient cohort , treat Cytarabine dose level ( 200 mg/m2-500 mg/m2-1000 mg/m2 ) combination drug Flag scheme fix dose Velcade 1,3 mg/m2 . Once appropriate Cytarabine dose determine , recruitment complete 40 patient evaluations visit program realize three period : Pre-treatment , Treatment Follow-up . The Pre-treatment include Screening baseline visit . After provide informed consent , patient evaluate study eligibility . Eligible patient include study receive first cycle , consist Fludarabine , Cytarabine Idarubicin combination 2 time per week Velcade administration . Each 28-day treatment , patient evaluate , absence disease progression unacceptable toxicity , patient start second cycle Bortezomib monotherapy two time per week follow 10 day rest period . That , patient response acceptable toxicity receive combine sequential scheme twice ( induction consolidation ) . Patients evaluate day 1 cycle , treatment period , order know response carry treatment . Once Treatment period complete , patient evaluate Follow-up period , one monthly visit year 1 , every 3 month 3 next year . On center criterion , autologous/allogeneic transplant plan depend age HLA identical sibling donor make possible : do follow sequential scheme ( Velcade-Flag-Ida Velcade monotherapy ) ; patient candidate transplant donor , he/she receive 2 sequential scheme . Safety evaluate adverse event monitoring , physical exploration , vital sign , hematimetric biochemical analysis . The treatment response evaluate use Cheson 's standardized criterion , MRD impact necessary evaluate day 1 new cycle carry treatment .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>The patient must , accord investigator criterion , able comply protocol requirement . The patient must sign voluntarily inform consent performance study relate procedure part usual medical care , knowledge leave study moment he/she want , without prejudice later medical care . Age ¡Ý 18 year old . Patient must diagnose AML accord World Health Organization ( WHO ) 18 criterion ( see Appendix 7 ) . Patient refractory AML standard therapy , relapse AML standard therapy hematopoietic progenitor transplant ( autologous allogenic ) . Patient ECOG performance status &lt; = 2 ( see Appendix 5 ) . Patient follow laboratory value Baseline visit : 1 . Platelet count ≥ 30000/mm3 ( transfusion allow ) , hemoglobin ≥ 8 g/dl ( transfusion allow ) absolute neutrophil count ≥ 0.750/mm3 . Lower value accept cause bone marrow infiltration . 2 . Aspartate transaminase ( AST ) : ≤ 2.5 x upper limit normal . 3 . Alanine transaminase ( ALT ) : ≤ 2.5 x upper limit normal . 4 . Total bilirubin : ≤1.5 x upper limit normal . 5 . Serum creatinine value ≤ 2 mg/dl . Negative pregnant test fertile female Prior Bortezomib therapy . Promyelocytic AML . Patient &gt; Grade 2 peripheral neuropathy within 14 day enrollment . Fertile patient go use medical effective contraceptive method trial . Patient receive investigational drug within 30 day enrollment . Patient known seropositive human immunodeficiency virus ( HIV ) , Hepatitis B surface antigenpositive active hepatitis C infection . Patient myocardial infarction within 6 month enrollment New York Heart Association ( NYHA ) Class III IV , heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Patient enrol another clinical research study and/or receive investigational agent reason . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>